Browsing by Subject "A5288; darunavir; drug resistance; LMIC; third-line ART; 144 weeks efficacy"

Now showing items 1-2 of 2

Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial

Avihingsanon, Anchalee; Hughes, Michael D.; Salata, Robert; Godfrey, Catherine; McCarthy, Caitlyn; Mugyenyi, Peter (Journal of the International AIDS Society, 2022-06)

Introduction: ACTG A5288 was a strategy trial conducted in diverse populations from multiple continents of people living with HIV (PLWH) failing second-line protease inhibitor (PI)-based antiretroviral therapy (ART) from ...
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial

Avihingsanon1, Anchalee; Hughes, Michael D.; Salata, Robert; Godfrey, Catherine; McCarthy, Caitlyn (Avihingsanon A et al. Journal of the International AIDS Society, 2022)

Introduction: ACTG A5288 was a strategy trial conducted in diverse populations from multiple continents of people living with HIV (PLWH) failing second-line protease inhibitor (PI)-based antiretroviral therapy (ART) from ...

Now showing items 1-2 of 2

Search DSpace